Taking a continuous 168-day course of oral contraceptives (OCs) can reduce symptoms of premenstrual syndrome, or PMS, compared to the 21/7-day regimen, according to the results of a study published in the November issue of the American Journal of Obstetrics and Gynecology.
Taking a continuous 168-day course of oral contraceptives (OCs) can reduce symptoms of premenstrual syndrome, or PMS, compared to the 21/7-day regimen, according to the results of a study published in the November issue of the American Journal of Obstetrics and Gynecology.
Andrea L. Coffee, PharmD, of Scott & White Memorial Hospital in Temple, Tex., and colleagues conducted a study of 111 women who had switched from a 21/7-day regimen of an OC containing 3 mg of drosperinone and 30 μg of ethinylestradiol to a continuous 168-day regimen.
A subgroup of 55 women (54%) with the greatest cyclical variation in physical symptoms and mood swings was identified and taken to resemble patients with premenstrual syndrome. Those women who experienced the most severe cyclic variability when taking the OCs on a 21/7-day basis benefited the most from a 168-day regimen, with the biggest improvement noted during the 6th month.
Coffee AL, Kuehl TJ, Willis S, et al. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol. 2006;195:1311-1319.
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More